Innoviva (INVA) Change in Receivables (2010 - 2026)
Innoviva posted quarterly Change in Receivables of -$961000.0 for Q1 2026, up 74.16% year-on-year from -$551792.3 in Q1 2025, and down 109.83% on a QoQ basis from $9.8 million in Q3 2025.
Innoviva (INVA) has 11 years of Change in Receivables data on file, last reported at -$961000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 74.16% year-over-year to -$961000.0; the trailing twelve-month figure through Mar 2026 stood at $9.3 million (down 62.16% YoY), and the FY2025 full-year result was $14.6 million, up 145.44% from the prior year.
- Change in Receivables for Q1 2026 stood at -$961000.0, down from $9.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $16.1 million in Q3 2024 and bottomed at -$3.7 million in Q1 2025.
- The 5-year median for Change in Receivables is $1.4 million (2023), against an average of $4.2 million.
- The widest annual swing landed in 2024, when Change in Receivables surged 5980.47%; it then tumbled 1080.63% in 2025.
- A 5-year view of Change in Receivables shows it stood at $867000.0 in 2022, then surged by 55.82% to $1.4 million in 2023, then soared by 1091.12% to $16.1 million in 2024, then plunged by 39.26% to $9.8 million in 2025, then tumbled by 109.83% to -$961000.0 in 2026.
- The last three Change in Receivables figures came in at -$961000.0 (Q1 2026), $9.8 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -961,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -961,000.00 |
| Mar 31, 2026 | -961,000.00 |
| Sep 30, 2025 | 9.78 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 4.25 Mn |
| Mar 31, 2025 | -3.72 Mn |
| Mar 31, 2025 | -3.72 Mn |
| Sep 30, 2024 | 16.09 Mn |
| Sep 30, 2024 | 16.09 Mn |
| Jun 30, 2024 | 12.64 Mn |
| Jun 30, 2024 | 12.64 Mn |
| Mar 31, 2024 | -315,000.00 |
| Mar 31, 2024 | -315,000.00 |
| Sep 30, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | -215,000.00 |
| Jun 30, 2023 | -215,000.00 |
| Mar 31, 2023 | 6.09 Mn |
| Mar 31, 2023 | 6.09 Mn |
| Sep 30, 2022 | 867,000.00 |
| Sep 30, 2022 | 867,000.00 |
| Jun 30, 2015 | 311,000.00 |
| Jun 30, 2015 | 311,000.00 |
| Mar 31, 2015 | -311,000.00 |
| Mar 31, 2015 | -311,000.00 |
| Dec 31, 2014 | -907,000.00 |
| Dec 31, 2014 | -907,000.00 |
| Sep 30, 2014 | 907,000.00 |
| Sep 30, 2014 | 907,000.00 |
| Jun 30, 2014 | -252,000.00 |
| Jun 30, 2014 | -252,000.00 |
| Mar 31, 2014 | 178,000.00 |
| Mar 31, 2014 | 178,000.00 |
| Dec 31, 2013 | -2.13 Mn |
| Dec 31, 2013 | -2.13 Mn |
| Sep 30, 2013 | 1.43 Mn |
| Sep 30, 2013 | 1.43 Mn |
| Dec 31, 2012 | 152,000.00 |
| Dec 31, 2012 | 152,000.00 |
| Sep 30, 2012 | -23,000.00 |
| Sep 30, 2012 | -23,000.00 |
| Jun 30, 2012 | 31,000.00 |
| Jun 30, 2012 | 31,000.00 |
| Mar 31, 2012 | -160,000.00 |
| Mar 31, 2012 | -160,000.00 |
| Dec 31, 2011 | 142,000.00 |
| Dec 31, 2011 | 142,000.00 |
| Sep 30, 2011 | -166,000.00 |
| Sep 30, 2011 | -166,000.00 |
| Jun 30, 2011 | 321,000.00 |
| Jun 30, 2011 | 321,000.00 |
| Mar 31, 2011 | -268,000.00 |
| Mar 31, 2011 | -268,000.00 |
| Dec 31, 2010 | -6,000.00 |
| Dec 31, 2010 | -6,000.00 |
| Sep 30, 2010 | -234,000.00 |
| Sep 30, 2010 | -234,000.00 |